ALG-000184

DRUG4 trials

Sponsors

Aligos Therapeutics Inc., Aligos Therapeutics

Conditions

Chronic Hepatitis BChronic Hepatitis B InfectionChronic Hepatitis B Virus InfectionHealthy Volunteer

Phase 1

A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

CompletedNCT04536337

Aligos TherapeuticsChronic Hepatitis B

Start: 2020-10-22End: 2025-06-16Updated: 2025-11-21

A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

Active, not recruitingNCT06672900

Aligos TherapeuticsHealthy Volunteer

Start: 2025-01-09End: 2025-07-07Updated: 2025-02-03

Phase 2

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

Active, not recruitingNCT06963710

Aligos TherapeuticsChronic Hepatitis B Infection

Start: 2025-07-15End: 2028-08-01Target: 200Updated: 2026-09-11

A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME)

RecruitingCTIS2025-521178-33-00

Aligos Therapeutics Inc.Chronic Hepatitis B Virus Infection

Start: 2025-12-03Target: 50Updated: 2025-11-19

Related Papers

ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial.

2026-01-16

A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants.

2025-11-21

Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.

2021-07-197 citations